HC Wainwright Has Strong Forecast for Insmed FY2027 Earnings

Insmed, Inc. (NASDAQ:INSM) – HC Wainwright increased their FY2027 earnings per share estimates for Insmed in a report released on Wednesday, April 8th. HC Wainwright analyst A. Fein now anticipates that the biopharmaceutical company will post earnings per share of $0.88 for the year, up from their prior estimate of $0.22. HC Wainwright currently has a “Buy” rating and a $245.00 target price on the stock. The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share. HC Wainwright also issued estimates for Insmed’s FY2028 earnings at $3.38 EPS, FY2029 earnings at $6.15 EPS and FY2030 earnings at $9.09 EPS.

A number of other research analysts also recently commented on the company. The Goldman Sachs Group increased their price target on Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a report on Monday, December 15th. Guggenheim reduced their price target on Insmed from $230.00 to $221.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Raymond James Financial began coverage on Insmed in a report on Friday. They issued an “outperform” rating and a $200.00 price target for the company. Citigroup reissued an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. Finally, Royal Bank Of Canada increased their price target on Insmed from $197.00 to $200.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Insmed has an average rating of “Buy” and an average target price of $212.09.

Insmed Trading Down 3.0%

Shares of INSM opened at $154.81 on Friday. The company has a market capitalization of $33.42 billion, a P/E ratio of -24.15 and a beta of 1.10. Insmed has a one year low of $63.81 and a one year high of $212.75. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The stock has a 50-day moving average price of $150.47 and a 200 day moving average price of $167.04.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The company had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. During the same quarter last year, the business posted ($1.32) EPS. Insmed’s quarterly revenue was up 152.6% compared to the same quarter last year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. CIBC Private Wealth Group LLC lifted its holdings in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the last quarter. CoreCap Advisors LLC bought a new position in Insmed during the 4th quarter worth approximately $27,000. Stone House Investment Management LLC bought a new position in Insmed during the 3rd quarter worth approximately $29,000. SBI Securities Co. Ltd. lifted its holdings in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 166 shares during the last quarter. Finally, GraniteShares Advisors LLC bought a new position in Insmed during the 4th quarter worth approximately $30,000.

Insiders Place Their Bets

In other Insmed news, CEO William Lewis sold 19,215 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the transaction, the chief executive officer owned 306,891 shares of the company’s stock, valued at $51,864,579. This trade represents a 5.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Michael Alexander Smith sold 19,638 shares of the stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $150.98, for a total value of $2,964,945.24. Following the transaction, the insider directly owned 51,871 shares in the company, valued at approximately $7,831,483.58. This represents a 27.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 198,992 shares of company stock valued at $31,660,112 in the last quarter. Insiders own 3.00% of the company’s stock.

Trending Headlines about Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Raymond James initiated coverage with an “Outperform” rating and a $200 price target, providing a near‑term upside anchor for the stock. The Fly
• Positive Sentiment: HC Wainwright updated its multi‑year model: it cut FY2030 EPS but materially raised FY2027–FY2029 estimates (FY2027 to $0.88, FY2028 to $3.38, FY2029 to $6.15), and maintains a $245 price objective — signaling improving medium‑term profitability assumptions from a major biotech analyst. MarketBeat: HC Wainwright updates
• Positive Sentiment: Large institutional holders (including Norges Bank and Vanguard) have built meaningful positions recently, which supports a structural bid under the stock and reduces free‑float supply pressure. MarketBeat: Institutional holdings
• Neutral Sentiment: Coverage pieces and valuation debates (e.g., “Is it too late to consider Insmed?”) are circulating; these frame the stock as recovery vs. valuation trade and may amplify headline trading but don’t change fundamentals on their own. Yahoo: Is it too late?
• Neutral Sentiment: CEO William Lewis sold 10,699 shares under a pre‑arranged Rule 10b5‑1 plan; the sale is material in dollar terms but was preplanned and follows a pattern of scheduled dispositions. SEC Form 4
• Negative Sentiment: Short interest rose sharply in March (roughly a 37% increase to ~13.8M shares, ~6.6% of the float, ~4.7 days to cover), raising downside pressure from bearish bets and amplifying volatility on negative headlines.
• Negative Sentiment: Insmed will discontinue development of brensocatib for hidradenitis suppurativa after the Phase 2b CEDAR trial missed primary/secondary endpoints (placebo outperformed), removing that potential revenue stream and driving the recent selloff and a trading halt on the study news. Reuters: Program discontinued
• Negative Sentiment: Market reaction to the trial miss included a trading halt and sharp intraday declines, signaling elevated near‑term downside risk and headline sensitivity. Investing.com: Market reaction

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.